Meiji Seika Pharma Expands Global CMO/CDMO Footprint at CPHI Milan 2026
Event summary
- Meiji Seika Pharma will debut at CPHI Milan 2026 (October 6–8, 2026) to showcase its CMO/CDMO services.
- The company will highlight 80 years of expertise in Japanese-quality manufacturing and a global network spanning Japan, Europe, India, and Southeast Asia.
- Medreich Limited, a subsidiary in India, will play a key role in demonstrating large-scale CMO/CDMO capabilities.
- The goal is to forge new global partnerships and expand its contract manufacturing business.
The big picture
Meiji Seika Pharma’s debut at CPHI Milan 2026 underscores the growing trend of pharmaceutical companies expanding their CMO/CDMO services globally. The company’s emphasis on Japanese-quality manufacturing and its extensive network position it to capitalize on rising demand for contract pharmaceutical manufacturing, particularly in emerging markets like India and Southeast Asia. The strategic move highlights the importance of local subsidiaries, such as Medreich Limited, in driving operational scale and market penetration.
What we're watching
- Global Expansion
- How Meiji Seika Pharma’s global manufacturing network will affect its competitiveness in the CMO/CDMO market.
- Execution Risk
- Whether the company can sustain its quality standards across its international facilities.
- Partnership Dynamics
- The pace at which Meiji Seika Pharma forges new partnerships at CPHI Milan 2026.
Related topics